Robert Muni-Lofra, PhD, University of Newcastle, Newcastle, UK, discusses the impact of disease-modifying therapies on the management of spinal muscular atrophy (SMA) and the role of a physiotherapist in the clinical management of SMA. As a physiotherapist, Dr Lofra emphasizes the importance of assessing the natural history of the condition and the need for a more granular assessment with the introduction of these therapies. The role of physiotherapists in understanding the changing phenotypes in SMA, the novel treatments, and how it affects patient care is essential. The introduction of these treatments is a challenge that prompts healthcare professionals to rethink their approach to providing care. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
